ERBB2 and breast carcinoma: The first clinical trial using HER2-targeted CAR-T cells for the treatment of metastatic HER2-positive breast cancer (NCT00924287) was terminated due to organ failure of normal HER2-expressing lung tissue by off-target recognition (151).